Disease areas
Over 170 known endocrine diseases affect all ages, often requiring lifelong treatment and significantly impacting quality of life. Many remain untreated or poorly managed.

Visen Pharmaceuticals is a biopharmaceutical company developing and commercializing endocrine therapies for Greater China.
visenpharma.comCrawled Nov 2, 2026
Over 170 known endocrine diseases affect all ages, often requiring lifelong treatment and significantly impacting quality of life. Many remain untreated or poorly managed.
Lonapegsomatropin is an investigational long-acting growth hormone designed for weekly dosing to help children with growth hormone deficiency reach or approach normal height. Phase 3 trials demonstrated its superiority over daily growth hormone formulations, with approvals in the United States (2021) and European Union (2022). A 2022 Chinese Phase 3 trial met primary endpoints, also showing superiority over daily growth hormone.
TransCon C-type natriuretic peptide is under investigation for treating achondroplasia in children, the most common form of short stature. It targets weekly dosing to potentially sustain inhibition of overactivated FGFR3 pathways, restoring normal chondrocyte differentiation and proliferation for systemic skeletal growth. Phase 2 trials in China began in January 2021.
TransCon parathyroid hormone is an investigational drug for hormone replacement therapy in adults with hypoparathyroidism (hypoparathyroidismism). It aims to restore near-physiological parathyroid hormone levels via stable blood concentrations, improving calcium and phosphorus regulation to alleviate daily physical and psychological symptoms while reducing long-term complication risks. Phase 3 trials began in China in May 2021, with enrollment completed in June 2022.
WeiSheng updates its pipeline of product developments.
TransCon technology temporarily connects carrier molecules with biologically active prototype drugs using a unique linkage structure. The resulting prodrugs can be designed for systemic or localized (e.g., tumor) action to achieve specific therapeutic goals. It applies to proteins, peptides, or small molecules across multiple treatment areas.
WeiSheng specializes in endocrine-related treatments, combining global expertise to enhance patient care and outcomes.
WeiSheng develops humanized therapies to improve life for endocrine patients, offering global treatment solutions to Chinese patients.
WeiSheng aims to provide human-centered therapies for endocrine patients and gathers global expertise to improve treatment outcomes.
Visen Pharmaceuticals obtains NMPA approval for **Skytrofa (lonapegsomatropin, TransCon hGH)**, a growth hormone therapy for children and adolescents aged 3+ with growth failure caused by growth hormone deficiency (GHD). The drug, developed in partnership with Ascendis Pharma, marks Visen’s first NMPA-approved pediatric treatment in this indication. The approval expands access to long-acting growth hormone therapy in China’s pediatric patient population.
VISEN Pharmaceuticals launches a **HK$783 million (≈US$101 million) IPO** on the Hong Kong Stock Exchange to fund late-stage treatments for endocrine diseases in Greater China. The offering includes a 15% overallotment option. Cooley serves as legal advisor for the biopharmaceutical company targeting near-commercialization therapies.
VISEN Pharmaceuticals (2561.HK) has initiated its initial public offering (IPO) on the Hong Kong Exchange (HKEx) main board. The company now accepts both margin and cash applications for the listing. This marks the first public market entry for the pharmaceutical firm.
VISEN Pharmaceuticals reports that its Phase 3 PaTHway China Trial of **Palopegteriparatide (TransCon PTH)** met primary and key secondary endpoints in treating **adults with chronic hypoparathyroidism**. The 26-week study, which was randomized, double-blind, and placebo-controlled, showed a statistically significant improvement in patients receiving the drug compared to placebo. The trial evaluates the drug’s efficacy in addressing this rare endocrine disorder.
VISEN Pharmaceuticals secures China National Medical Products Administration (NMPA) acceptance for its Biologics License Application (BLA) of **Lonapegsomatropin (TransCon hGH)**, a once-weekly growth hormone treatment. The drug is already approved by the **U.S. FDA** and **European Medicines Agency (EMA)** for endocrine disease management. VISEN specializes in innovative biopharmaceutical solutions targeting hormonal disorders.
VISEN Pharmaceuticals releases pivotal phase 3 trial data for **lonapegsomatropin**, a weekly injectable growth hormone therapy for children with growth hormone deficiency (GHD) in China. The study evaluates the long-acting prodrug of unmodified somatropin as an alternative to daily injections. Results detail clinical efficacy and safety metrics from the trial.
VISEN reports its Phase 3 trial of **TransCon™ hGH** meets the primary endpoint, showing pediatric patients with growth hormone deficiency (GHD) achieve **greater annualized height velocity** after 52 weeks of once-weekly treatment compared to daily growth hormone (p=0.0010). The results align with Ascendis Pharma’s earlier Phase 3 **heiGHt** trial. The trial evaluates a weekly injection formulation for GHD management.
VISEN Pharmaceuticals secures **$150 million in Series B funding** to advance its pipeline of **endocrine-focused therapies** targeting unmet medical needs in Greater China. The capital will support both **development and commercialization** of its innovative drug candidates. The company specializes in addressing gaps in patient care within the region’s endocrine disease landscape.